Comparison of Two Assays for Serum 1,5-Anhydroglucitol

Selvin, Elizabeth; Rynders, Gregory P.; Steffes, Michael W.

doi:10.1016/j.cca.2011.01.007

Cited by 27 publications

(30 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reliability coefficient for 610 masked duplicate sample pairs was 0.99 (10). Previous studies have shown this 1,5-AG assay is reliable in long-term stored samples (24,25). …”

Section: Methodsmentioning

confidence: 67%

See 1 more Smart Citation

Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular Disease

et al. 2016

Self Cite

View full text Add to dashboard Cite

OBJECTIVE1,5-Anhydroglucitol (1,5-AG) is a biomarker of glucose peaks and has been associated with clinical cardiovascular disease. However, the association between 1,5-AG and subclinical cardiovascular disease is unknown. We investigated the association of 1,5-AG with subclinical myocardial damage (assessed by high-sensitivity cardiac troponin T [hs-cTnT]) and atherosclerosis (assessed by carotid intima-media thickness [CIMT] and carotid plaque).RESEARCH DESIGN AND METHODSWe measured 1,5-AG, hs-cTnT, CIMT, and carotid plaque among 10,072 people without diabetes and 681 with diabetes who attended the second examination of the Atherosclerosis Risk in Communities (ARIC) Study (baseline, 1990–1992). We used Poisson regression to characterize the associations between 1,5-AG and prevalent elevated hs-cTnT, thick CIMT, or carotid plaque. Among 9,145 people with a second hs-cTnT measurement 6 years later, we used multinomial logistic regression to assess associations with incident elevation in hs-cTnT.RESULTSWe found that in people with diabetes, lower 1,5-AG (<6 μg/mL) was cross-sectionally associated with elevated hs-cTnT (prevalence ratio 2.06, 95% CI 1.23–3.46) compared with higher 1,5-AG (≥10 μg/mL). Associations in people without diabetes and with thick CIMT or the presence of carotid plaque were less robust. Low 1,5-AG was prospectively associated with the 6-year incident elevation in hs-cTnT (relative risk 2.90, 95% CI 1.23–6.85) in people with diabetes. All associations were strongly attenuated with further adjustment for HbA1c.CONCLUSIONSIn people with diabetes, 1,5-AG was associated with subclinical cardiovascular disease, particularly chronic subclinical myocardial damage. Nonetheless, whether observed associations are truly independent of average glycemia is unclear.

show abstract

“…The reliability coefficient for 610 masked duplicate sample pairs was 0.99 (10). Previous studies have shown this 1,5-AG assay is reliable in long-term stored samples (24,25). …”

Section: Methodsmentioning

confidence: 67%

“…Details of the GlycoMark assay have been previously described elsewhere (24). The interassay coefficient of variation (CV) was 5%.…”

Section: Methodsmentioning

confidence: 99%

Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular Disease

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The reliability coefficient for N=610 masked duplicate specimen pairs was 0.99. Previous studies have shown this 1,5-AG assay to be reliable in long-term stored samples (11, 12). …”

Section: Methodsmentioning

confidence: 76%

Association of 1,5-Anhydroglucitol with Diabetes and Microvascular Conditions

et al. 2014

Self Cite

View full text Add to dashboard Cite

Background 1,5-anhydroglucitol (1,5-AG) is inversely related to hyperglycemia and may be a useful indicator of short-term (1-2 week) hyperglycemia and glycemic excursions but its prognostic value is unclear. We sought to evaluate the associations of 1,5-AG with risk of diabetes and microvascular disease. Methods We measured 1,5-AG in blood samples from over 10,000 participants in the ARIC Study (baseline, 1990-1992) and characterized the independent associations with prevalent retinopathy, and with incident chronic kidney disease and incident diabetes during approximately 20 years of follow-up. Results We found that 1,5-AG was associated with prevalent retinopathy, driven primarily by the strong association in persons with diagnosed diabetes: adjusted OR 11.26 (95%CI 6.17-20.53) for <6 ug/mL compared to 1,5-AG ≥10 ug/mL. This result remained significant after further adjustment for HbA1c (OR 4.85, 95%CI 2.42-9.74). In persons with diagnosed diabetes: low 1,5-AG (<6 ug/mL vs ≥10 ug/mL) was also associated with a greater than 2-fold increased risk of incident chronic kidney disease (adjusted HR 2.83, 95% CI 2.15-3.74) and remained significant after adjustment for HbA1c (HR 1.43, 95%CI 1.02-2.00). Nondiabetic participants with high 1,5-AG (≥ 10 ug/mL) had the lowest prevalence of retinopathy and lowest risk of kidney disease. In persons without diagnosed diabetes at baseline, 1,5-AG <10 ug/mL was also associated with incident diabetes (adjusted HR 2.29, 95%CI 2.03-2.58). Conclusions 1,5-AG was associated with long-term risk of important microvascular outcomes, particularly in persons with diagnosed diabetes and even after adjustment for HbA1c. Our results suggest 1,5-AG may capture risk information associated with hyperglycemic excursions.

show abstract

“…The interassay coefficients of variation were: 4.8% (1,5-AG, mean 19.4 μg/mL), 3.7% (fructosamine, mean 254.9 μmol/L), and 2.7% (glycated albumin, mean 12.8%). Previous studies have demonstrated high stability of these measurements in stored serum samples (12–14). …”

Section: Methodsmentioning

confidence: 87%

Associations of Alternative Markers of Glycemia with Hemoglobin A1c and Fasting Glucose

2012

Self Cite

View full text Add to dashboard Cite

BACKGROUND 1,5-anhydroglucitol (1,5-AG), fructosamine, and glycated albumin are of increasing interest as alternative measures of hyperglycemia. We characterize the associations of these nontraditional glycemic markers with hemoglobin A1c (HbA1c) and fasting glucose and assess their ability to identify people with diabetes. METHODS We conducted a cross-sectional comparison of 1,5-AG, fructosamine, and glycated albumin with HbA1c and fasting glucose measurements in 1,719 participants from the Atherosclerosis Risk in Communities (ARIC) Study. Non-linear relationships were evaluated using R2 and F-statistics. Performance for identifying cases of diabetes was determined using the Area Under the Curve (AUC). Diabetes was defined by HbA1c ≥6.5%, fasting glucose ≥126 mg/dL (≥6.99 mmol/L), and/or a self-reported history of diagnosed diabetes. RESULTS Median values of HbA1c and fasting glucose were 5.8% and 109 mg/dL (6.05 mmol/L), respectively; 17.3% of the study population had diagnosed diabetes. Glycated albumin, fructosamine, and 1,5-AG were more strongly correlated with HbA1c compared with fasting glucose (all P-values <0.05). Nonlinear models provided the best fit for describing the relationships of the alternative markers to HbA1c. When diabetes was defined by an HbA1c≥6.5%, fructosamine (AUC 0.83; 95% CI: 0.79–0.87) and glycated albumin (AUC 0.87; 95% CI: 0.83–0.90) performed comparably to fasting glucose (AUC 0.83; 95% CI: 0.79–0.87), while 1,5-AG performed worse (AUC 0.74; 95% CI: 0.69–0.78) for identifying cases of undiagnosed diabetes. CONCLUSIONS Fructosamine and glycated albumin may be useful adjuncts to HbA1c and fasting glucose. Future studies should examine these markers in situations where fasting glucose or HbA1c measurements are invalid or not available.

show abstract

Comparison of Two Assays for Serum 1,5-Anhydroglucitol

Cited by 27 publications

References 7 publications

Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular Disease

Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular Disease

Association of 1,5-Anhydroglucitol with Diabetes and Microvascular Conditions

Associations of Alternative Markers of Glycemia with Hemoglobin A1c and Fasting Glucose

Contact Info

Product

Resources

About